Add Formweb to your mobile device
Search results for:
enoxaparin
enoxaparin
| Drug Name | Form | Strength | Notes |
|---|---|---|---|
| Lovenox | SOLUTION, INJECTABLE | 30 mg/0.3 mL | |
| Lovenox | SOLUTION, INJECTABLE | 40 mg/0.4 mL | |
| Lovenox | SOLUTION, INJECTABLE | 60 mg/0.6 mL | |
| Lovenox | SOLUTION, INJECTABLE | 80 mg/0.8 mL | |
| Lovenox | SOLUTION, INJECTABLE | 100 mg/mL | |
| Lovenox | SOLUTION, INJECTABLE | 120 mg/0.8 mL | |
| Lovenox | SOLUTION, INJECTABLE | 150 mg/mL | |
| Lovenox | SOLUTION, INJECTABLE | 300 mg/3 mL |
Last updated: Sep. 30, 2022
- High Alert: CAUTION: See High-Alert Medication Policy
- Black Box Warning: Spinal/epidural hematoma risk
enoxaparin
Dosing/Monitoring Protocols & Guidelines
Adult
Treatment dosing: see Protocol 900.6521
VTE prophylaxis in Trauma Patients: see Protocol 910.5002
Antithrombotic and Anticoagulant Treatment in Stroke: See 900.5018
Pediatric
Dosing and Monitoring: Protocol 912.6010
Surgical Guidelines
Periprocedural Management of Anticoagulation therapy: See Protocol 900.5011
Neuraxial Anesthesia and Anticoagulation: Guideline 900.5681
Reversal Guidelines:
Reversal of enoxaparin in Adults: See Reversal Guideline 900.5010
Reversal of enoxaparin in Pediatrics: See Reversal Guideline 900.5866
Patient education/assistance:
Anticoagulation Education: LH Intranet Materials
Anticoagulant Management: Policy 900.3207